Last reviewed · How we verify

Canthardin Collodion — Competitive Intelligence Brief

Canthardin Collodion (Canthardin Collodion) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vesicant / keratolytic agent. Area: Dermatology.

marketed Vesicant / keratolytic agent Protein phosphatase 2A (PP2A) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Canthardin Collodion (Canthardin Collodion) — Medical University of South Carolina. Cantharidin causes blister formation and tissue necrosis by inhibiting protein phosphatase 2A, leading to acantholysis and epidermal-dermal separation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Canthardin Collodion TARGET Canthardin Collodion Medical University of South Carolina marketed Vesicant / keratolytic agent Protein phosphatase 2A (PP2A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vesicant / keratolytic agent class)

  1. Medical University of South Carolina · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Canthardin Collodion — Competitive Intelligence Brief. https://druglandscape.com/ci/canthardin-collodion. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: